Martine Vugt - Genmab AS Executive Officer
| GMAB Stock | USD 20.04 0.21 1.04% |
Executive
Ms. Martine J. van Vugt, Ph.D. serves as Chief of Staff at Genmab AS. She has knowledge and experience in portfolio, project and alliance management, as well as business development operations related to corporate transactions and licensing.
| Age | 54 |
| Address | Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500 |
| Phone | 45 70 20 27 28 |
| Web | https://www.genmab.com |
Genmab AS Management Efficiency
The company has return on total asset (ROA) of 0.1091 % which means that it generated a profit of $0.1091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2297 %, meaning that it created $0.2297 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.27. The current year's Return On Capital Employed is expected to grow to 0.17. At present, Genmab AS's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 18.9 B, whereas Other Current Assets are forecasted to decline to about 110.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Janet Graesser | Vaxcyte | N/A | |
| Andrew Gengos | Terns Pharmaceuticals | 61 | |
| Yuhong Qiu | Legend Biotech Corp | N/A | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Joseph Kelly | Ascendis Pharma AS | 56 | |
| Michael CPA | Blueprint Medicines Corp | 53 | |
| Adam Townsend | Apellis Pharmaceuticals | 47 | |
| Andrew Callos | Cytokinetics | 55 | |
| Camille MD | Amylyx Pharmaceuticals | 72 | |
| Nivi Nehra | Travere Therapeutics | N/A | |
| Patrick Lamy | Akero Therapeutics | 52 | |
| Elvia Cowan | Vaxcyte | 52 | |
| Katie Hogan | Alector | N/A | |
| Harp MBA | Vaxcyte | 51 | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Sam Iki | Vaxcyte | N/A | |
| Deborah Wong | Legend Biotech Corp | N/A | |
| Charlotte Smith | Travere Therapeutics | N/A | |
Management Performance
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.11 |
Genmab AS Leadership Team
Elected by the shareholders, the Genmab AS's board of directors comprises two types of representatives: Genmab AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab AS's management team and ensure that shareholders' interests are well served. Genmab AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Takahiro Hamatani, Senior Director | ||
| Birgitte MSc, Executive Officer | ||
| Marisol Peron, Senior Affairs | ||
| Christopher Cozic, Executive Officer | ||
| Tahamtan Ahmadi, Senior Vice President Oncology and Translational Medicine | ||
| Anthony CPA, Executive CFO | ||
| Anthony Mancini, Executive COO | ||
| Judith MD, Executive Officer | ||
| Anthony Pagano, Senior Vice President Global Finance and Corporate Development | ||
| Martine Vugt, Executive Officer | ||
| Andrew Carlsen, Senior Director, Investor Relations | ||
| Peter Ros, Sr Accounting | ||
| Martin Schultz, Senior Director | ||
| Rayne Waller, Executive Officer | ||
| Jan Winkel, President CoFounder | ||
| Mijke Zachariasse, Director Director | ||
| Rima Nassar, Head VP | ||
| Tahamtan MD, Chief VP |
Genmab Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genmab AS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.36 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 10.04 B | ||||
| Shares Outstanding | 635.5 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 9.31 % | ||||
| Number Of Shares Shorted | 1.65 M | ||||
| Price To Earning | 66.53 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.634 | Earnings Share 1.77 | Revenue Per Share | Quarterly Revenue Growth 0.353 | Return On Assets |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.